Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

COVID-19 Infection Raises Myasthenia Gravis Exacerbation Risk

COVID-19 Omicron infection increases the risk of exacerbation in myastheniagravis (MG) patients, especially those with comorbidities or on immunosuppressive therapy. The study highlights the need for precise vaccines to protect MG patients, offering hope for better management and support during infections. 

Subcutaneous Efgartigimod Demonstrates Efficacy, Safety in Seronegative Myasthenia Gravis

The phase 3 ADAPT-SC study shows subcutaneous efgartigimod is safe and effective for seronegative myasthenia gravis patients. Improvements in daily living and quality of life were noted, with mild side effects. This offers hope for a previously overlooked group, enhancing treatment accessibility and patient well-being. 

Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis

The KYSA-6 trial explores KYV-101 CAR-T therapy for myasthenia gravis, aiming to improve daily living activities. Involving 20 patients, it assesses safety and efficacy over 24 weeks. The study, cleared by the FDA, offers hope for those with limited treatment options, focusing on positive patient outcomes. 

Understanding Patient Perspectives Around Myasthenia Gravis Treatment

The study highlights the importance of considering patient preferences in myasthenia gravis treatment to improve well-being. Patients express frustration over treatment inertia and symptom neglect. They prioritise fast-acting, effective treatments with minimal side effects. Understanding these perspectives can enhance quality of life and treatment satisfaction.